FrancophonIA/ELRC3.0 huggingface dataset:
English: In a randomised, open-label trial, a total of 399 previously untreated elderly patients (age 60 to 80 years) with diffuse large B cell lymphoma received standard CHOP chemotherapy (cyclophosphamide 750 mg/m2, doxorubicin 50 mg/m2, vincristine 1.4 mg/m2 up to a maximum of 2 mg on day 1, and prednisolone 40 mg/m2/day on days 1-5) every 3 weeks for eight cycles, or rituximab 375 mg/m2 plus CHOP (R-CHOP).
Croatian: U randomiziranom otvorenom ispitivanju ukupno je 399 prethodno neliječenih starijih bolesnika (u dobi od 60 do 80 godina) s difuznim limfomom velikih B-stanica primalo standardnu CHOP kemoterapiju (ciklofosfamid 750 mg/m2, doksorubicin 50 mg/m2, vinkristin 1,4 mg/m2 do najviše 2 mg prvog dana liječenja te prednizolon 40 mg/m2/dan od prvog do petog dana liječenja) svaka 3 tjedna u osam ciklusa liječenja, ili rituksimab u dozi od 375 mg/m2 u kombinaciji s CHOP kemoterapijom (R-CHOP).
English: EFS - Event Free Survival TTP - Time to progression or death PFS - Progression-Free Survival TTF - Time to Treatment Failure OS rates - survival rates at the time of the analyses
Croatian: Time to progression or death) PFS - preživljenje bez progresije bolesti (engl.
English: Further, significantly higher proportion of patients achieved MCIDs for these scores (Table 14).
Croatian: Nadalje, značajno je veći udio bolesnika postigao
English: Very rare cases of fatal PML have been reported following the use of rituximab.
Croatian: Nakon primjene rituksimaba prijavljeni su vrlo rijetki slučajevi PML-a sa smrtnim ishodom.
English: Table 15 Summary of efficacy by baseline autoantibody status Week 24
Croatian: Sažetak djelotvornosti prema početnom statusu autoantitijela
English: The most frequent adverse reactions considered due to receipt of rituximab were IRRs.
Croatian: Najčešće nuspojave koje se smatraju posljedicom primjene rituksimaba bile su reakcije povezane s infuzijom.
English: Ritemvia is indicated for the treatment of previously untreated patients with stage III-IV follicular lymphoma in combination with chemotherapy.
Croatian: Ritemvia je u kombinaciji s kemoterapijom indicirana u liječenju bolesnika oboljelih od folikularnog limfoma stadija III-IV koji prethodno nisu liječeni.
English: Influenza-like illness Oedema peripheral
Croatian: Opći poremećaji i reakcije na mjestu primjene vrućica bolest nalik gripi periferni edem
English: Rituximab maintenance treatment consisted of a single infusion of rituximab at 375 mg/m2 body surface area given every 3 months until disease progression or for a maximum period of two years.
Croatian: Terapija održavanja rituksimabom sastojala se od primjene jedne infuzije rituksimaba u dozi od 375 mg/m2 tjelesne površine svaka tri mjeseca do progresije bolesti ili najdulje dvije godine.
English: Figure 2: ACR responses for 4 treatment courses (24 weeks after each course (within patient, within visit) in patients with an inadequate response to TNF-inhibitors (n=146)
Croatian: (intraindividualno, unutar posjeta) u bolesnika koji nisu dovoljno dobro odgovorili na TNF-inhibitore (n = 146)
English: Mean pre-therapeutic antibody titres against a panel of antigens (Streptococcus pneumoniae, influenza A, mumps, rubella, varicella) were maintained for at least 6 months after treatment with rituximab.
Croatian: zaušnjaci, rubela, varičela) prije terapije održala se najmanje 6 mjeseci nakon liječenja rituksimabom.
English: The safety profile of rituximab in patients with moderate to severe rheumatoid arthritis (RA) is summarised in the sections below.
Croatian: Sigurnosni profil rituksimaba u bolesnika sa srednje teškim ili teškim reumatoidnim artritisom (RA)
English: Rheumatoid arthritis, granulomatosis with polyangiitis, microscopic polyangiitis, and pemphigus vulgaris
Croatian: Reumatoidni artritis, granulomatoza s poliangiitisom, mikroskopski poliangiitis i obični pemfigus
English: In the pivotal trial, 166 patients with relapsed or chemoresistant low-grade or follicular B cell NHL received 375 mg/m2 of rituximab as an intravenous infusion once weekly for four weeks.
Croatian: U pivotalnom je ispitivanju 166 bolesnika s relapsirajućim ili kemorezistentnim, nisko malignim ili folikularnim B-staničnim ne-Hodgkinovim limfomom primilo rituksimab u dozi od 375 mg/m2 putem intravenske infuzije jedanput tjedno tijekom četiri tjedna.
English: Dizziness Tremor
Croatian: Probavni poremećaji
English: Table 3 Adverse drug reactions occurring at 6-months in ≥ 5% of patients receiving rituximab for induction of remission of GPA and MPA, and at a higher frequency than the comparator group, in the pivotal clinical study.
Croatian: Tablica 3 Nuspojave koje su u 6 mjeseci nastupile u ≥ 5 % bolesnika koji su primali lijek rituksimab za poticanje remisije GPA i MPA i koje su se javile s većom učestalošću nego u usporednoj skupini Organski sustav Nuspojava
English: Ritemvia 500 mg concentrate for solution for infusion
Croatian: Ritemvia 500 mg koncentrat za otopinu za infuziju
English: Cases of posterior reversible encephalopathy syndrome (PRES)/reversible posterior leukoencephalopathy syndrome (RPLS) have been reported in autoimmune conditions.
Croatian: Neurološki događaji Prijavljeni su slučajevi sindroma reverzibilne posteriorne encefalopatije (engl. posterior reversible encephalopathy syndrome, PRES) odnosno sindroma reverzibilne posteriorne leukoencefalopatije (engl. reversible posterior leukoencephalopathy syndrome, RPLS) u autoimunim stanjima.
English: Non-Hodgkin's lymphoma
Croatian: Ne-Hodgkinov limfom
English: Granulomatosis with polyangiitis and microscopic polyangiitis
Croatian: Granulomatoza s poliangiitisom i mikroskopski poliangiitis
English: Infusion-related reactions in the pemphigus vulgaris clinical study were common (58%).
Croatian: Reakcije povezane s infuzijom bile su česte (58%) u kliničkim ispitivanjima kod običnog pemfigusa.
English: Decreased haemoglobin
Croatian: Pretrage snižene razine hemoglobina
English: Experience from granulomatosis with polyangiitis and microscopic polyangiitis
Croatian: Iskustva s primjenom kod granulomatoze s poliangitisom i mikroskopskog poliangitisa
English: Table 4 Adverse drug reactions occurring in ≥ 5% of patients receiving rituximab for maintenance treatment of GPA and MPA, and at a higher frequency than the comparator group
Croatian: Tablica 4 Nuspojave koje su nastupile u ≥ 5% bolesnika koji su primali lijek rituksimab za terapiju održavanja GPA i MPA i koje su se javile s većom učestalošću nego u usporednoj skupini Organski sustav
English: 3infusion-related reactions (hypertension, nausea, rash, pyrexia, pruritus, urticaria, throat irritation, hot flush, hypotension, rhinitis, rigors, tachycardia, fatigue, oropharyngeal pain, peripheral oedema, erythma)
Croatian: urtikarija, iritacija grla, navale vrućine, hipotenzija, rinitis, tresavica, tahikardija, umor, bol u ustima i ždrijelu, periferni edem, eritem)
English: Name:_______________________ Doctor's contact details:________________ Make sure you have a list of all your medicines when you see a health care professional.
Croatian: Kad posjećujete zdravstvenog djelatnika, obavezno sa sobom ponesite popis svih lijekova koje uzimate.
English: ORR was 38% (CI95% 26% - 51%; 10% CR, 28% PR) with a projected median TTP for responding patients of 17.8 months (range 5.4 - 26.6).
Croatian: 26 % - 51 %; CR 10 %, PR 28 %), a procijenjeni medijan TTP-a u bolesnika koji su odgovorili na liječenje 17,8 mjeseci (raspon 5,4-26,6 mjeseci).
English: Repeated treatment courses with Ritemvia are possible.
Croatian: Ritemvia mogu se ponavljati.
English: • blocked or runny nose
Croatian: • začepljen nos curenje iz nosa
English: In an open-label randomised trial, a total of 322 previously untreated patients with follicular lymphoma were randomised to receive either CVP chemotherapy (cyclophosphamide 750 mg/m2, vincristine 1.4 mg/m2 up to a maximum of 2 mg on day 1, and prednisolone 40 mg/m2/day on days 1-5) every 3 weeks for 8 cycles or rituximab 375 mg/m2 in combination with CVP (R-CVP).
Croatian: U otvorenom randomiziranom ispitivanju ukupno su 322 prethodno neliječena bolesnika s folikularnim limfomom slučajnim odabirom određena za primanje CVP kemoterapije (ciklofosfamid 750 mg/m2, vinkristin 1,4 mg/m2 do najviše 2 mg prvog dana liječenja, prednizolon 40 mg/m2/dan od prvog do petog dana liječenja) svaka 3 tjedna u 8 ciklusa liječenja, ili rituksimaba u dozi od 375 mg/m2 u kombinaciji s CVP kemoterapijom (R-CVP).
English: 4.06 years
Croatian: 4,06 godina 10.149 godina
English: Ritemvia 100 mg concentrate for solution for infusion
Croatian: Ritemvia 100 mg koncentrat za otopinu za infuziju
English: This syndrome may be associated with some features of tumour lysis syndrome such as hyperuricaemia, hyperkalaemia, hypocalcaemia, hyperphosphataemia, acute renal failure, elevated lactate dehydrogenase (LDH) and may be associated with acute respiratory failure and death.
Croatian: hipokalcijemijom, hiperfosfatemijom, akutnim zatajenjem bubrega, povišenom razinom laktat dehidrogenaze (LDH), kao i s akutnim zatajenjem dišnog sustava i smrću.
English: In the clinical trial evaluating rituximab maintenance treatment in relapsed/refractory follicular lymphoma, median IgG levels were below the lower limit of normal (LLN) (< 7 g/L) after induction treatment in both the observation and the rituximab groups.
Croatian: IgG-a nakon početne terapije bio je ispod donje granice normalnih vrijednosti (< 7 g/l) i u opservacijskoj skupini i u skupini koja je primala rituksimab.
English: Patients treated with rituximab in combination with methotrexate had a significantly greater reduction in disease activity score (DAS28) than patients treated with methotrexate alone (Table 12).
Croatian: U bolesnika liječenih rituksimabom u kombinaciji s metotreksatom došlo je do značajno većeg smanjenja aktivnosti bolesti (DAS28, od engl.
English: Patients with a history of a serious infusion reaction to a biologic therapy for RA were excluded from entry.
Croatian: U ispitivanje nisu mogli biti uključeni bolesnici koji su u anamnezi imali ozbiljnu infuzijsku reakciju na neki biološki lijek za reumatoidni artritis.
English: Alopecia Pruritus Urticaria Skin disorder
Croatian: Poremećaji kože i potkožnog tkiva alopecija svrbež urtikarija poremećaj kože
English: The mean Cmax (N=15) was 408 µg/mL (range, 97 - 764 µg/mL) after the fifth 500 mg/m2
Croatian: Prosječni Cmax (N = 15) nakon pete infuzije od 500 mg/m2
English: Experience from non-Hodgkin's lymphoma and chronic lymphocytic leukaemia
Croatian: Iskustva s primjenom u ne-Hodgkinovu limfomu i kroničnoj limfocitnoj leukemiji
English: 150 patients originally randomised to placebo + MTX in Trial 1 received at least one course of RTX + MTX by one year * p <0.05, ** p < 0.001.
Croatian: 150 bolesnika prvotno nasumično raspodijeljenih u skupinu koja je primala placebo + metotreksat u Ispitivanju 1 primilo je barem jedan ciklus terapije rituksimab + metotreksat do kraja jedne godine ispitivanja
English: Mean change in SF‐36 MHS
Croatian: Srednja vrijednost promjene SF-36 MHS % bolesnika sa SF-36 MHS MCID
English: Common Uncommon Rare
Croatian: Obični pemfigus
English: 1 vial contains 500 mg of rituximab.
Croatian: 1 bočica sadrži 500 mg rituksimaba.
English: • painful joints or back
Croatian: • umor ili omaglica
English: 9.25 years log-rank p value hazard ratio (95% CI) risk reduction TNLT (median)
Croatian: (medijan) log-rang p-vrijednost omjer hazarda (95% CI) smanjenje rizika TNLT (medijan)
English: Contraindications for use in rheumatoid arthritis, granulomatosis with polyangiitis, microscopic polyangiitis and pemphigus vulgaris
Croatian: Kontraindikacije za primjenu kod reumatoidnog artritisa, granulomatoze s poliangiitisom, mikroskopskog poliangiitisa i običnog pemfigusa
English: The frequencies of ADRs reported with rituximab alone or in combination with chemotherapy are summarised in Table 1.
Croatian: Učestalost nuspojava prijavljenih pri primjeni rituksimaba u monoterapiji ili u kombinaciji s kemoterapijom sažeta je u Tablici
English: In the clinical trial on induction of remission, cardiac events occurred at a rate of approximately 273 per 100 patient years (95% CI 149-470) at the 6-month primary endpoint.
Croatian: 273 na 100 bolesnik-godina (95 % CI 149-470) u trenutku primarne mjere ishoda nakon 6 mjeseci.
English: fungal infections, infections of unknown origin, sinus inflammation, hepatitis B
Croatian: gljivična infekcija, infekcije nepoznate etiologije, +akutni bronhitis, +sinusitis, hepatitis B1
English: Blood and lymphatic system disorders neutropenia, leucopenia, +febrile neutropenia, +thrombocytope nia anaemia, +pancytopenia, +granulocytope nia coagulation disorders, aplastic anaemia, haemolytic anaemia, lymphadenopa thy transient increase in serum IgM levels3
Croatian: Poremećaji krvi i limfnog sustava neutropenija, leukopenija, +febrilna neutropenija, +trombocitopenija anemija, +pancitopenija, +granulocitopenija poremećaji zgrušavanja,
English: Table 10b First-line treatment of chronic lymphocytic leukaemia Hazard ratios of progression-free survival according to Binet stage (ITT) - 48.1 months median observation time Number of Patients
Croatian: Omjeri hazarda za preživljenje bez progresije bolesti prema Binetovom stadiju (ITT populacija) - medijan vremena promatranja je 48,1 mjesec Preživljenje bez progresije bolesti (PFS)
English: No patients were withdrawn due to ADRs.
Croatian: Nijedan bolesnik nije prekinuo liječenje zbog nuspojava.
English: Also do not breast-feed for 12 months after your last treatment with Ritemvia.
Croatian: Ne smijete dojiti dijete tijekom liječenja lijekom Ritemvia i još 12 mjeseci nakon posljednje primjene lijeka jer se Ritemvia može izlučiti u majčino mlijeko.
English: Package leaflet: Information for the patient Ritemvia 500 mg concentrate for solution for infusion rituximab This medicine is subject to additional monitoring.
Croatian: Uputa o lijeku: Informacije za bolesnika Ritemvia 500 mg koncentrat za otopinu za infuziju rituksimab
English: In CLL, the overall incidence of grade 3 or 4 cardiac disorders was low both in the first-line study (4% R-FC, 3% FC) and in the relapsed/refractory study (4% R-FC, 4% FC).
Croatian: 3 ili 4 bila niska i u ispitivanju prve linije liječenja (4 % R-FC, 3 % FC) i u ispitivanju relapsirajuće/refraktorne bolesti (4 % R-FC, 4 % FC).
English: If you have granulomatosis with polyangiitis, microscopic polyangiitis or pemphigus vulgaris also tell your doctor
Croatian: Imate li granulomatozu s poliangiitisom, mikroskopski poliangiitis ili obični pemfigus,
English: however transient B-cell depletion and lymphocytopenia have been reported in some infants born to mothers exposed to rituximab during pregnancy.
Croatian: Ne postoje odgovarajući i dobro kontrolirani podaci iz ispitivanja u trudnica, no u neke dojenčadi čije su majke tijekom trudnoće bile izložene rituksimabu prijavljene su prolazna deplecija B-stanica i limfocitopenija.
English: The cumulative incidence rate curves showed that time to first major relapse was longer in patients with rituximab starting from month 2 and was maintained up to month 28 (Figure 3).
Croatian: Krivulje kumulativne stope incidencije pokazuju dulje vrijeme do prvog teškog relapsa u bolesnika liječenih lijekom rituksimab.
English: In all patients subgroups (gender, age, age adjusted IPI, Ann Arbor stage, ECOG, β2 microglobulin, LDH,
Croatian: IPI), Ann Arbor stadij, ECOG (engl.
English: Musculoskeletal disorders arthralgia / musculoskeletal pain, osteoarthritis, bursitis
Croatian: Poremećaji mišićno-koštanog sustava artralgija/bol u kostima i mišićima,
English: Package leaflet: Information for the patient Ritemvia 100 mg concentrate for solution for infusion rituximab This medicine is subject to additional monitoring.
Croatian: Uputa o lijeku: Informacije za bolesnika Ritemvia 100 mg koncentrat za otopinu za infuziju rituksimab
English: Common side effects (may affect up to 1 in 10 people): infections such as herpes infections and eye infection mood disorders such as irritability and depression skin disorders such as itching, hives, and benign lumps feeling tired or dizzy fever headache pain in the tummy pain in the muscles heart beating faster than normal
Croatian: Manje česte nuspojave (mogu se javiti u do 1 na 100 osoba): tegobe sa zgrušavanjem krvi, smanjeno stvaranje crvenih krvnih stanica i pojačano uništavanje crvenih krvnih stanica (aplastična hemolitička anemija), otečeni ili povećani limfni čvorovi neraspoloženost i gubitak interesa ili zadovoljstva u obavljanju aktivnosti, nervoza tegobe s osjetom okusa - poput promjena u okusu srčane tegobe - kao što su usporeno kucanje srca ili bol u prsnom košu (angina)
English: Sodium chloride Tri-sodium citrate dihydrate Polysorbate 80
Croatian: FARMACEUTSKI PODACI 6.1 Popis pomoćnih tvari natrijev klorid natrijev citrat dihidrat polisorbat 80 voda za injekcije
English: Table 10a First-line treatment of chronic lymphocytic leukaemia Overview of efficacy results for rituximab plus FC vs. FC alone - 48.1 months median observation time Efficacy Parameter
Croatian: Pregled rezultata djelotvornosti za rituksimab + FC u odnosu na samo FC (medijan vremena promatranja je 48,1 mjesec) Parametar djelotvornosti
English: Respiratory, thoracic and mediastinal disorders
Croatian: Poremećaji dišnog sustava, prsišta i sredoprsja dispneja
English: The recommended dose of Ritemvia monotherapy used as induction treatment for adult patients with stage III-IV follicular lymphoma who are chemoresistant or are in their second or subsequent relapse after chemotherapy is: 375 mg/m2 body surface area, administered as an intravenous infusion once weekly for 4 weeks.
Croatian: • Relapsirajući/refraktorni folikularni limfom Preporučena doza lijeka Ritemvia u monoterapiji kod uvodnog liječenja odraslih bolesnika oboljelih od folikularnog limfoma stadija III-IV koji su rezistentni na kemoterapiju ili su u drugom odnosno sljedećem relapsu nakon kemoterapije iznosi 375 mg/m2 površine tijela, a primjenjuje se u obliku intravenske infuzije jedanput tjedno tijekom četiri tjedna.
English: This is because some people have a fall in their blood pressure while they are being given Ritemvia.
Croatian: 12 sati prije primjene lijeka Ritemvia zato što nekim bolesnicima može pasti krvni tlak tijekom primjene lijeka Ritemvia.
English: You might get infections more easily during your treatment with Ritemvia.
Croatian: Tijekom liječenja lijekom Ritemvia možda ćete biti podložniji infekcijama.
English: Following two intravenous infusions of rituximab at a dose of 1000 mg, two weeks apart, the mean terminal half-life was 20.8 days (range, 8.58 to 35.9 days), mean systemic clearance was 0.23 L/day (range, 0.091 to 0.67 L/day), and mean steady-state distribution volume was 4.6 L (range, 1.7 to 7.51 L).
Croatian: Nakon dvije intravenske infuzije rituksimaba u dozi od 1000 mg u razmaku od dva tjedna prosječan terminalni poluvijek bio je 20,8 dana (raspon 8,58 do 35,9 dana), prosječan sistemski klirens
English: b) If you are being treated for granulomatosis with polyangiitis or microscopic polyangiitis
Croatian: b) Bolesnici koji se liječe od granulomatoze s poliangiitisom ili mikroskopskog poliangiitisa
English: Maintenance and relapse
Croatian: Blagi relapsi
English: General disorders and administratio n site conditions fever, chills, asthenia, headache tumour pain, flushing, malaise, cold syndrome, +fatigue, +shivering, +multi-organ failure4
Croatian: astenija, glavobolja bol u predjelu tumora, navale crvenila, opća slabost, sindrom prehlade, +umor, +drhtavica, +zatajenje više organa4
English: If you are being treated for non-Hodgkin's Lymphoma
Croatian: a) Bolesnici koji se liječe od ne-Hodgkinova limfoma
English: Fatigue Pyrexia
Croatian: Razine IgG-a
English: The vial contains 500 mg of rituximab.
Croatian: Bočica sadrži 500 mg rituksimaba.
English: Follicular lymphoma
Croatian: Folikularni limfom Monoterapija
English: Mean change from baseline: Modified total sharp score Erosion score Joint space narrowing score Proportion of patients with no radiographic change
Croatian: Srednja vrijednost promjene od početnih vrijednosti: Prilagođen ukupan rezultat na Sharpovoj ljestvici
English: Regular full blood counts, including neutrophil and platelet counts, should be performed during rituximab therapy.
Croatian: Tijekom terapije lijekom rituksimaba potrebno je redovito kontrolirati kompletnu krvnu sliku, uključujući broj neutrofila i trombocita.
English: The recommended dose of Ritemvia in combination with chemotherapy for induction treatment of previously untreated or relapsed/ refractory patients with follicular lymphoma is: 375 mg/m2 body surface area per cycle, for up to 8 cycles.
Croatian: Preporučena doza lijeka Ritemvia u kombinaciji s kemoterapijom za uvodno liječenje bolesnika s prethodno neliječenim ili relapsirajućim/refraktornim folikularnim limfomom iznosi 375 mg/m2
English: 1 vial contains 100 mg of rituximab.
Croatian: 1 bočica sadrži 100 mg rituksimaba.
English: Hypogammaglobulinaemia (IgA, IgG or IgM below the lower limit of normal) has been observed in granulomatosis with polyangiitis and microscopic polyangiitis patients treated with rituximab.
Croatian: U bolesnika s granulomatozom s poliangiitisom i mikroskopskim poliangiitisom liječenih rituksimabom opažena je hipogamaglobulinemija (IgA, IgG ili IgM ispod donje granice normalnih vrijednosti).
English: The vial contains 100 mg of rituximab.
Croatian: Bočica sadrži 100 mg rituksimaba.
English: • being sick (vomiting), diarrhoea, pain in the stomach, irritation or ulcers in the throat and mouth, problems swallowing, constipation, indigestion
Croatian: • koprivnjača, pojačano znojenje, noćno znojenje mišićne tegobe - kao što je napetost u mišićima, bol u zglobovima ili mišićima, bol u vratu i leđima opća nelagoda, uznemirenost ili umor, drhtanje, znakovi gripe zatajenje više organa
English: Other side effects include: a) If you are being treated for non-Hodgkin's Lymphoma
Croatian: Koliko ćete lijeka primiti i koliko često a) Bolesnici koji se liječe od ne-Hodgkinova limfoma ako se liječite samo lijekom Ritemvia
English: Events of neutropenia were observed with rituximab treatment, the majority of which were transient and mild or moderate in severity.
Croatian: Tijekom liječenja rituksimabom zabilježeni su slučajevi neutropenije koji su većinom bili prolazni te blagog do umjerenog intenziteta.
English: • allergic reactions (hypersensitivity)
Croatian: 3reakcije povezane s infuzijom (hipertenzija,
English: Other symptoms included flushing, angioedema, bronchospasm, vomiting, nausea, urticaria/rash, fatigue, headache, throat irritation, rhinitis, pruritus, pain, tachycardia, hypertension, hypotension, dyspnoea, dyspepsia, asthenia and features of tumour lysis syndrome.
Croatian: glavobolju, iritaciju grla, rinitis, svrbež, bol, tahikardiju, hipertenziju, hipotenziju, dispneju, dispepsiju, asteniju te obilježja sindroma lize tumora.
English: Combination therapy
Croatian: Razlika između terapija
English: Patient subpopulations - rituximab combination therapy Elderly patients (≥ 65 years)
Croatian: Podskupine bolesnika - liječenje rituksimabom u kombinaciji
English: Following induction of remission with Ritemvia, maintenance treatment should be initiated no sooner than 16 weeks after the last Ritemvia infusion.
Croatian: Nakon primjene lijeka Ritemvia za poticanje remisije, terapiju održavanja treba započeti najmanje 16
English: • unusual feelings of the skin - such as numbness, tingling, pricking, burning, a creeping skin feeling, reduced sense of touch
Croatian: • poremećaji raspoloženja poput razdražljivosti i depresije • poremećaji kože poput svrbeža, koprivnjače i dobroćudnih kvržica
English: Ritemvia 500 mg concentrate for solution for infusion Rituximab
Croatian: Ritemvia 500 mg koncentrat za otopinu za infuziju rituksimab
English: Ritemvia is indicated for the treatment of patients with CD20 positive diffuse large B cell non-Hodgkin's lymphoma in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) chemotherapy.
Croatian: Ritemvia je u kombinaciji s CHOP kemoterapijom (ciklofosfamid, doksorubicin, vinkristin,